Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
HER2 inhibitor
DRUG CLASS:
HER2 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
trastuzumab (362)
afatinib (216)
lapatinib (105)
neratinib (99)
pyrotinib (63)
tucatinib (32)
trastuzumab-pkrb (23)
margetuximab (17)
poziotinib (15)
MCLA-128 (15)
KN026 (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
mobocertinib (7)
Zercepac (trastuzumab biosimilar) (7)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
TAS2940 (4)
DZD9008 (3)
Bay846 (2)
inetetamab (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
pertuzumab/trastuzumab/hyaluronidase-zzxf (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
AST-301 (1)
Hercease (trastuzumab biosimilar) (1)
CT-0508 (1)
EG12014 (trastuzumab biosimilar) (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
MP0274 (1)
ORIC-114 (1)
SAR443216 (1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
S-222611 (1)
MET306 (1)
KD019 (1)
trastuzumab-IFN-β mutein (1)
trastuzumab (362)
afatinib (216)
lapatinib (105)
neratinib (99)
pyrotinib (63)
tucatinib (32)
trastuzumab-pkrb (23)
margetuximab (17)
poziotinib (15)
MCLA-128 (15)
KN026 (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
LZM-005 (8)
PRS-343 (8)
mobocertinib (7)
Zercepac (trastuzumab biosimilar) (7)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
TAS2940 (4)
DZD9008 (3)
Bay846 (2)
inetetamab (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
pertuzumab/trastuzumab/hyaluronidase-zzxf (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
AST-301 (1)
Hercease (trastuzumab biosimilar) (1)
CT-0508 (1)
EG12014 (trastuzumab biosimilar) (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
MP0274 (1)
ORIC-114 (1)
SAR443216 (1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
S-222611 (1)
MET306 (1)
KD019 (1)
trastuzumab-IFN-β mutein (1)
›
Associations
(1029)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Colon Cancer
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1wk
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
HER-2 amplification + RAS wild-type + BRAF wild-type
Rectal Cancer
HER-2 amplification + RAS wild-type + BRAF wild-type
Rectal Cancer
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week (New A2)
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1wk
trastuzumab + tucatinib
Sensitive: A2 - Guideline
NCCN - 1 week
trastuzumab + tucatinib
Sensitive
:
A2
NCCN - 1 week - (New A2)
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
RET fusion + TP53 mutation
HER2 Positive Breast Cancer
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1wk
pyrotinib
Resistant: C4 – Case Studies
Anticancer Drugs - 1 week
pyrotinib
Resistant
:
C4
Anticancer Drugs - 1 week - (New C4)
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 1 week (New D)
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 1wk
dasatinib + lapatinib
Sensitive: D – Preclinical
PLoS One - 1 week
dasatinib + lapatinib
Sensitive
:
D
PLoS One - 1 week - (New D)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks (New A1)
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2wk
trastuzumab + tucatinib
Sensitive: A1 - Approval
FDA - 2 weeks
trastuzumab + tucatinib
Sensitive
:
A1
FDA - 2 weeks - (New A1)
HER-2 expression
Gastroesophageal Cancer
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
BRAF wild-type + HER-2 positive
Colorectal Cancer
BRAF wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type + HER-2 positive
Colorectal Cancer
RAS wild-type + HER-2 positive
Colorectal Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2wk
camrelizumab + pyrotinib
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
camrelizumab + pyrotinib
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
KRAS mutation
Biliary Tract Cancer
KRAS mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
ERBB3 mutation + HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 amplification
Biliary Tract Cancer
HER-2 amplification
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks (New A1)
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3wk
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3 weeks - (New A1)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
trastuzumab + tucatinib
Sensitive: A1 - Approval
trastuzumab + tucatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
trastuzumab + pertuzumab
Sensitive: A1 - Approval
trastuzumab + pertuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
margetuximab
Sensitive: A1 - Approval
margetuximab
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
Gastric Cancer
HER-2 positive
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
pembrolizumab + trastuzumab
Sensitive: A1 - Approval
pembrolizumab + trastuzumab
Sensitive
:
A1
HR positive
HER2 Positive Breast Cancer
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
neratinib
Sensitive: A1 - Approval
neratinib
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
trastuzumab
Sensitive: A1 - Approval
trastuzumab
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: A1 - Approval
pertuzumab / trastuzumab / hyaluronidase-zzxf
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
trastuzumab-qyyp
Sensitive: A1 - Approval
trastuzumab-qyyp
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
trastuzumab-dttb
Sensitive: A1 - Approval
trastuzumab-dttb
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
HER2 Positive Breast Cancer
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
trastuzumab-dkst
Sensitive: A1 - Approval
trastuzumab-dkst
Sensitive
:
A1
HER-2 amplification
Hormone Receptor Positive Breast Cancer
HER-2 amplification
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
HER-2 overexpression
Hormone Receptor Positive Breast Cancer
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
trastuzumab-anns
Sensitive: A1 - Approval
trastuzumab-anns
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login